Extended Data Fig. 8: Imatinib, MPA, and QNHC inhibit SARS-CoV-2 on Vero cells.
From: Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
a. qRT–PCR based dose curve of imatinib, MPA and QNHC on Vero cells at 24 h post-SARS-CoV-2 infection (SARS-CoV-2, MOI = 0.01). n = 3 biological independent experiments. b, c, Western blotting (b) and quantification (c) of 3 μM MPA, 4.5 μM QNHC or DMSO-treated Vero cells at 24 h post-SARS-CoV-2 infection (SARS-CoV-2, MOI = 0.01). n = 3 biological independent experiments, ***P = 0.000223, ***P = 5.09E-05, ***P = 4.32E-05. ***P = 3.72E-08. d, e, Western blotting (d) and quantification (e) of DMSO or 10 μM imatinib treated Vero cells at 24 hpi (SARS-CoV-2, MOI = 0.01). n = 3 biological independent experiments, ***P = 7.41E-18, ***P = 8.06E-07, ***P = 7.41E-18, ***P = 3.39E-06. ***P < 0.001. Data were analysed by an unpaired two-tailed Student’s t-test and shown as mean ± STDEV. Data are representative of at least three independent experiments.
